Longitudinal plasma biomarker study measuring Aβ42:Aβ40 ratio, p-tau181, NfL, and GFAP at midlife and late life in 1525 ARIC participants found that decreasing Aβ42:Aβ40 and increasing p-tau181, NfL,

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting APOE in human. Primary outcome: Longitudinal plasma biomarker study measuring Aβ42:Aβ40 ratio, p-tau181, NfL, and GFAP at midlife an

Description

Plasma biomarkers measured using Quanterix Simoa platform; incident dementia ascertained from neuropsychological assessments, participant contact, and medical record surveillance from 2012-2019.

TARGET GENE

APOE (Score: 0.621)

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

lipid metabolism/apolipoprotein function

SOURCE

pmid_39068543

PRIMARY OUTCOME

Longitudinal plasma biomarker study measuring Aβ42:Aβ40 ratio, p-tau181, NfL, and GFAP at midlife and late life in 1525 ARIC participants found that decreasing Aβ42:Aβ40 and increasing p-tau181, NfL, and GFAP over time were associated with incident all-cause dementia, with the strongest late-life association for NfL (HR 1.92).

Scoring Dimensions

Related Hypotheses (6)

TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM0.708

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia0.827

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)0.795

Competitive APOE4 Domain Stabilization Peptides0.784

APOE4-Specific Proteolytic Fragment Inhibition Therapy0.777

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.